A record of what Angel One said publicly, with the source. Not advice.
Angel One
Market analysis from this source
Graded calls
1 hit · 4 miss
Pending
19 awaiting resolution
Scored on trackable calls only. Long-horizon and commentary opinions are listed below but not counted in this score.
Recent analysis
Newest first. Every call links back to its original source.
| Call | Instrument | Verdict | Actions |
|---|---|---|---|
| “Bullish on Shanti Gold International with a target price of ₹410, implying a 30% upside from its October 28 closing pric…” | Gold | PENDING | |
| “Bullish on Aarti Pharmalabs with a target price of ₹1,160, based on 24 times its estimated FY29 EPS of ₹48. Expects earn…” | Aarti Pharmalabs Ltd | PENDING | |
| “Bullish on Northern Arc Capital with a target price of ₹330, based on approximately 6.1 times its estimated FY29 EPS of …” | Northern Arc Capital Ltd | PENDING | |
| “Bullish on ICICI Bank with a target price of ₹1,800, based on 18.8 times its estimated FY29 EPS of ₹95.70, factoring in …” | ICICI Bank | PENDING | |
| “Upgraded Bajaj Finance from 'Hold' to 'Buy' with a target price of ₹1,150, implying over 20% upside. Q2 NII was in line,…” | Bajaj Finance | PENDING | |
| “Maintains a 'Buy' rating on Axis Bank and increased its target price to ₹1,590. The Q2 FY27 profit was marginally lower …” | Axis Bank | PENDING | |
| “Maintains a BUY rating on ICICI Bank with a target price of ₹1,800, translating into 36.2% potential upside. The bank is…” | ICICI Bank | PENDING | |
| “Retains a BUY rating on SBI Life Insurance Company with a target price of ₹2,380, indicating 40% potential upside from c…” | SBI Life Insurance | PENDING | |
| “Maintains a BUY rating on Jindal SAW with a target price of ₹423, implying 52.2% potential upside. This is supported by …” | Jindal Saw Ltd | PENDING | |
| “Overweight on Healthcare and power/energy-related themes, neutral on Industrials due to elevated valuations, and neutral…” | Nifty 50 | — | |
| “Maintains a BUY rating on ITC with a target price of ₹440, implying 67.3% upside. The brokerage expects calibrated cigar…” | ITC | PENDING | |
| “Bullish on SBI Life Insurance Company with a target price of ₹2,380. Margins are expected to normalise as the product mi…” | SBI | PENDING | |
| “Bullish on Aurobindo Pharma with a target price of ₹1,840. Several growth triggers are identified, including Eugia, PenG…” | Aurobindo Pharma | HIT | |
| “Bullish on ITC with a target price of ₹440. Pricing power is expected to outweigh cigarette volume declines following re…” | ITC | PENDING | |
| “Bullish on Coal India with a target price of ₹516. The outlook is supported by expected increases in coal offtake as pla…” | Coal India Ltd | PENDING | |
| “Bullish on The Supreme Industries with a target price of ₹4,661. The positive outlook is supported by strong volume grow…” | Supreme Industries | PENDING | |
| “Bullish on NTPC with a target price of ₹455. Strong power demand and improving coal-based Plant Load Factor (PLF) are ex…” | NTPC Ltd | PENDING | |
| “Bullish on Jindal SAW with a target price of ₹423. Execution is expected to improve from Q3FY27 due to alternative logis…” | Jindal Saw Ltd | PENDING | |
| “Bullish on ICICI Bank with a target price of ₹1,800. Strong credit growth and a healthy liability franchise are expected…” | ICICI Bank | PENDING | |
| “Maintains a 'buy' rating on ITC with an unchanged target price of ₹440 per share. The brokerage believes the recent weak…” | ITC | PENDING | |
| “Maintains a BUY rating on ITC with an unchanged target price of ₹440 per share, implying a potential upside of 68% from …” | ITC | PENDING | |
| “Recommends a 'Subscribe' rating for Sri Lotus Developers IPO for long-term investors. The valuation at a post-issue P/E …” | Sri Lotus Developers | — | |
| “Bullish on Ashok Leyland with a 'buy' call and a target price of ₹295, implying an almost 18% upside from the previous c…” | Ashok Leyland | MISS | |
| “Angel One has initiated a "Buy" rating on Apollo Hospitals, citing its diversified healthcare portfolio and aggressive e…” | Angel One | — | |
| “Recommends buying Ashok Leyland in the ₹200-205 range, targeting ₹265 with a stop loss at ₹189. The stock has faced sell…” | Ashok Leyland | PENDING |
By instrument
Graded calls broken down by what was being called.
Aurobindo Pharma
1 hit · 0 miss
SBI
0 hit · 1 miss
Ashok Leyland
0 hit · 1 miss
JK Cement Ltd
0 hit · 1 miss
Hindustan Aeronautics Ltd
0 hit · 1 miss
Gold
1 pending
Aarti Pharmalabs Ltd
1 pending
ICICI Bank
3 pending
Bajaj Finance
1 pending
Axis Bank
1 pending
SBI Life Insurance
1 pending
Jindal Saw Ltd
2 pending
ITC
4 pending
Coal India Ltd
1 pending
NTPC Ltd
1 pending
Nifty 50
0 pending